Antibe Therapeutics Inc.
Antibe Therapeutics Inc. (ATBPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
atbpf · pe ratio · data through Mar 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Antibe Therapeutics Inc. (ATBPF) measures how much investors pay for each dollar of the company's trailing earnings. ATBPF's current PE ratio of N/A is calculated by dividing its stock price of $0.22 by its TTM earnings per share of -$0.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-03-31
PE Ratio History
2012 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Antibe Therapeutics Inc.You ATBPF | $11M | N/A | — | -$0.37 |
 Cloud DX Inc. CDXFF | $10M | N/A | — | -$0.11 |
 RIV Capital Inc. CNPOF | $11M | N/A | — | -$0.59 |
 Eiger BioPharmaceuticals, Inc. EIGRQ | $13M | N/A | — | -$50.78 |
 Living Cell Technologies Limited LVCLY | $11M | N/A | — | -$0.01 |
 LexaGene Holdings Inc. LXXGF | $11M | N/A | — | -$0.09 |
 MGC Pharmaceuticals Limited MGCLF | $12M | N/A | — | -$7.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-03-31Latest FY2023 | — | $-0.37 | — | |
2022-03-31 FY2022 | — | $-0.49 | — | |
2021-03-31 FY2021 | — | $-0.71 | — | |
2020-03-31 FY2020 | — | $-0.71 | — | |
2019-03-31 FY2019 | — | $-0.60 | — | |
2018-03-31 FY2018 | — | $-0.49 | — | |
2017-03-31 FY2017 | — | $-0.60 | — | |
2016-03-31 FY2016 | — | $-0.54 | — | |
2015-03-31 FY2015 | — | $-1.19 | — | |
2014-03-31 FY2014 | — | $-1.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Antibe Therapeutics Inc. (ATBPF) measures how much investors pay for each dollar of the company's trailing earnings. ATBPF's current PE ratio of N/A is calculated by dividing its stock price of $0.22 by its TTM earnings per share of -$0.37.
Frequently asked questions
ATBPF pe ratio · 6 questionsATBPF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.22 and TTM EPS of -$0.37. Data sourced from Financial Modeling Prep via ATBPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Antibe Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09